CloudMD Reports Second Quarter 2023 CloudMD Continues to Drive Execution with Adjusted EBITDA Approaching Breakeven
This was CloudMD’s third consecutive quarter of improving Adjusted EBITDA, representing a $2.5 million improvement year over year.
- This was CloudMD’s third consecutive quarter of improving Adjusted EBITDA, representing a $2.5 million improvement year over year.
- On August 23rd, 2023, CloudMD announced the signing of a significant contract to provide Remote Patient Monitoring to a major U.S.
- Both Gross Margin and Adjusted EBITDA have seen continuous improvement quarter over quarter and our goal for Adjusted EBITDA breakeven in Q4 2023 is within reach.
- Q2 2023 Adjusted EBITDA1 of ($0.7) million, compared to Adjusted EBITDA1 of ($1.4) million in Q1 2023 and compared to ($3.2) million in Q2 2022.